ArticleWorld journal of urology2010
A rat model of intravesical delivery of small interfering RNA for studying urinary carcinoma.
Article in World journal of urology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 8 citations in OpenAlex.
- Recent advances in imaging and understanding interstitial cystitis.F1000Research · 2018Review
- SiRNA Crosslinked Nanoparticles for the Treatment of Inflammation-induced Liver Injury.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2017Article
- Intravesical liposome and antisense treatment for detrusor overactivity and interstitial cystitis/painful bladder syndrome.ISRN pharmacology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposesiRNA has been used successfully in loss-of-function studies in vitro, but neither in vivo nor in clinical applications. The aims of the present study were (1) to establish rat models for in vivo delivery of siRNA to bladder cancer, and (2) to identify potential targets for siRNA.
methodsThe rat models of human urinary carcinoma and rat urinary carcinoma cell line (AY-27) were induced by tobacco-related chemical carcinogens, either N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide (FANFT) or N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN). A syngeneic orthotopic bladder cancer model was established by inoculation of AY-27 cells. A fluorescence-labelled negative control siRNA with cationic and neutral liposomes was tested both in vitro (AY-27 cells) and in vivo.
resultssiRNA was highly accumulated in the cancer cells as early as 12 h and remained at least for 24 h after a single dose in vivo. Numerous CD3+ T cells appeared mainly in the periphery area of the tumour. Bioinformatics analysis revealed a list of concordantly highly expressed genes, possible siRNA targets, in the animal models as well as human urinary carcinoma. Literature search on siRNA and bladder cancer provided a list of genes used as siRNA targets.
conclusionThe methodology and data presented in the present study provide a number of opportunities for basic research on urinary carcinogenesis and for translational research on evaluation of siRNA therapeutic strategies for urinary carcinoma in the native organ, where hormonal, neural and immunological processes more closely resemble the clinical situation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.